Amanta Healthcare Commences Manufacturing At New Steriport Facility In Kheda

Market snapshot: Amanta Healthcare has officially commenced commercial production at its newly expanded SteriPort manufacturing facility (Line 3) at its Kheda campus in Gujarat. This development represents the resolution of a one-quarter civil delay and signifies the formal launch of a key post-IPO capacity-led growth phase.

Data Snapshot

• SteriPort Line 3 construction and equipment capex funded via IPO proceeds
• Flagship Large Volume Parenteral (LVP) capacity scale-up from 6.6 crore units to 11.6 crore units annually
• Captive solar power plant capacity commissioned at Matar, Kheda, to support energy consumption
• Reported standalone operational revenue for the first quarter of fiscal year 2027

What's Changed

• Amanta's flagship SteriPort capacity expanded from 6.6 crore bottles to 11.6 crore bottles per year.
• The business transitions from bearing pre-operative overheads to generating active commercial revenue from SteriPort Line 3.
• Energy logistics upgraded following the successful commissioning of a 10.8 MWp solar project, saving ₹75 lakh monthly.

Key Takeaways

• Production commencement resolves the main growth bottleneck, unlocking high-margin parenteral capacity.
• Capex scaling is structurally supported by ₹70 crore of the ₹126 crore raised during the September 2025 IPO.
• Operating leverage will begin reducing the overhead drag that temporarily depressed Q1 FY27 EBITDA margins to 22%.
• Amanta is well-positioned with a dominant 50–60% domestic market share in the premium PP IV bottle segment.

SAHI Perspective

The operationalization of SteriPort Line 3 is the ultimate litmus test for Amanta's capacity-led growth thesis. The temporary consolidation in stock price following Q1 FY27 results was a direct function of pre-operative overhead absorption without active production. Now active, this line will capture significant domestic and export demand, driving EBITDA margins toward management's 25–26% target.

Market Implications

With the SteriPort capacity delay resolved, the overhang on the stock's valuation should dissipate. The transition to higher-volume, premium self-collapsing sterile parenteral bottles should accelerate top-line execution, targeting a peak operational revenue threshold of ₹425 crore by fiscal year 2028, leading to potential margin-led re-ratings.

Trading Signals

Market Bias: Bullish

Commencement of SteriPort Line 3 unlocks the capacity-led expansion model, converting absorbed pre-operative overheads into high-margin revenue. This supports volume-driven growth towards a peak capability of 11.6 crore units.

Overweight: Sterile Injectables, Pharmaceutical Formulations

Trigger Factors:

• Capacity utilization and order ramp-up rate for SteriPort Line 3.
• Commissioning of the Small Volume Parenteral (SVP) expansion in Q4 FY27.
• Raw material pricing trends, specifically polypropylene and polymer inputs.

Time Horizon: Medium-term (3-12 months)

Industry Context

Amanta Healthcare operates in the niche, high-barrier sterile liquid parenteral space. The segment requires strict compliance with WHO-GMP and international standards. Traditional glass packaging is increasingly replaced by advanced polymer two-port systems (such as SteriPort), where pricing power is relatively stronger and shielded from aggressive regulatory price caps.

Key Risks to Watch

• Fluctuations in polymer and crude oil derivative costs which could strain gross margins.
• Single-location operational risk, as all manufacturing remains concentrated at the Hariyala facility in Kheda.
• Export timelines and regulatory audit clearances in target advanced markets.

Recent Developments

Amanta Healthcare commissioned a 10.8 MWp captive solar power plant in Kheda on May 30, 2026, which is expected to yield approximately ₹9 crore in annual energy savings. Additionally, the company reported stable Q1 FY27 results on August 5, 2026, with revenue of ₹68.8 crore and a net profit of ₹3.3 crore, navigating input cost pressures via strategic pricing corrections.

Closing Insight

Amanta's transition from a highly leveraged pre-IPO player to a well-capitalized, structurally efficient manufacturer is taking shape. The launch of SteriPort Line 3 is the fundamental catalyst that translates capex into cash flows, turning structural efficiency into a clear competitive advantage.

High Performance Trading with SAHI.